The International Community of Women Living with HIV Eastern Africa (ICWEA) welcomes and affirms the approval of Lenacapavir (LEN)—a twice-yearly injectable HIV prevention option—by the Uganda National Drug Authority as the right and timely decision for Uganda.
Uganda’s approval is especially significant given that Uganda was one of the countries where Lenacapavir clinical studies were conducted, with Ugandan communities, researchers, and advocates playing a direct role in generating the evidence that informed this milestone. It is both scientifically sound and ethically right that communities who contributed to the science now benefit from its outcomes.
Read our statement here: ICWEA STATEMENT ON THE APPROVAL OF LENACAPAVIR FOR HIV PREVENTION IN UGANDA
